Gene · 4017
Papers2,536
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 2,536
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism. | Cell Oncol (Dordr) | 2023 | 36454513 | PubTator, text mining | PubMed |
| DNA methylation signature aberration as potential biomarkers in treatment-resistant schizophrenia: Constructing a methylation risk score using a machine learning method. | J Psychiatr Res | 2023 | 36442407 | PubTator, text mining | PubMed |
| Myelofibrosis. | Blood | 2023 | 36416738 | PubTator, text mining | PubMed |
| The Dietary Isothiocyanate Erucin Reduces Kidney Cell Motility by Disturbing Tubulin Polymerization. | Mol Nutr Food Res | 2023 | 36415106 | PubTator, text mining | PubMed |
| Protein disulfide isomerase A3 activity promotes extracellular accumulation of proteins relevant to basal breast cancer outcomes in human MDA-MB-A231 breast cancer cells. | Am J Physiol Cell Physiol | 2023 | 36374169 | PubTator, text mining | PubMed |
| MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer. | Clin Transl Oncol | 2023 | 36355327 | PubTator, text mining | PubMed |
| Serum levels of lysyl oxidase-like 2 are increased in patients with dermatomyositis. | Clin Exp Rheumatol | 2023 | 36200946 | PubTator, text mining | PubMed |
| Liver Organoids, Novel and Promising Modalities for Exploring and Repairing Liver Injury. | Stem Cell Rev Rep | 2023 | 36199007 | PubTator, text mining | PubMed |
| LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry. | Dig Liver Dis | 2023 | 36192339 | PubTator, text mining | PubMed |
| Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. | Gut | 2023 | 35428659 | PubTator, text mining | PubMed |
| LOXL2 in pancreatic tumourigenesis: the complexity of tumour-stromal crosstalk exemplified. | Gut | 2023 | 35428658 | PubTator, text mining | PubMed |
| Genome-wide DNA methylome and transcriptome changes induced by inorganic nanoparticles in human kidney cells after chronic exposure. | Cell Biol Toxicol | 2023 | 34973136 | PubTator, text mining | PubMed |
| Extracellular matrix in cancer progression and therapy. | Med Rev (2021) | 2022 | 37724245 | PubTator, text mining | PubMed |
| Preclinical models for development of immune-oncology therapies. | Immuno-oncol Insights | 2022 | 37132013 | PubTator, text mining | PubMed |
| Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome. | Cancer Res Commun | 2022 | 36923555 | PubTator, text mining | PubMed |
| Stromal cells support the survival of human primary chronic lymphocytic leukemia (CLL) cells through Lyn-driven extracellular vesicles. | Front Med (Lausanne) | 2022 | 36714146 | PubTator, text mining | PubMed |
| A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer. | Front Pharmacol | 2022 | 36699089 | PubTator, text mining | PubMed |
| Tumour microenvironment landscape and immunotherapy response in bladder cancer decoded by stromal MOXD1 based on copper-related genes signature. | Front Oncol | 2022 | 36620542 | PubTator, text mining | PubMed |
| Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression. | Front Cell Dev Biol | 2022 | 36619866 | PubTator, text mining | PubMed |
| A prognostic estimation model based on mRNA-sequence data for patients with oligodendroglioma. | Front Neurol | 2022 | 36588901 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4017/papers?page=27